People with any condition that affects the liver over a long period of time can develop cirrhosis. Conditions that can lead to cirrhosis include alcohol excess, liver steatosis (lipid or fat accumulation in the liver) and infection with hepatitis B and C. One concern about people with cirrhosis is that they are at increased risk of developing liver cancer. People with cirrhosis are recommended to have an ultrasound scan (USS) every 6 months (surveillance) so that if a cancer develops, ...

GO TO STUDY

Our musculoskeletal system is essential for movement and to give our body structure. The system is made up of bones (skeleton) and soft connective tissues (muscles, tendons, cartilage and ligaments )that enable the skeleton to move. These tissues contain cells that work together to help the tissue function and grow normally. Our musculoskeletal system changes continuously from infancy to adulthood, with each tissue type changing in both size and shape, and they become less effective at repairing themselves when injured. Our ...

GO TO STUDY

Parkinson's disease (PD) is the second commonest neurodegenerative disorder, affecting over 145,000 people in the UK. Initially, PD patients experience slowness of movements, limb stiffness, and tremor. With progressive loss of neurons over time, many patients start to experience balance and walking problems, and falls, which are resistant to currently available treatments. Falls can lead to fractures and nursing home admission, and can significantly shorten patients' life expectancy. In this pilot study, we will investigate the effects of spinal ...

GO TO STUDY

Resection of liver metastases from colorectal cancer (CRLM) improves survival compared to chemotherapy alone and may lead to cure. In some cases the liver metastasis are considered unresectable. A common reason for this is the lack of enough "tumour free" liver for the patient to survive the operation (Future liver remnant -FLR-). In the event of insufficient FLR, there is a great proportion of patients that will develop liver disfunction that can lead to death (post-hepatectomy liver failure is the ...

GO TO STUDY

There are Four treatment groups using a 1:1:1:1 ratio, who will receive a study treatment for 24 weeks. For intervention group amlitelimab + GF, they will have amlitelimab 500mg loading dose followed by a 250mg dose once every four weeks + gluten free products for the full 24 weeks. Intervention group placebo + Gluten free, will have matching placebo and gluten free products for the full 24 weeks. The amlitelimab + SIGE (simulated inadvertent gluten exposure) group, will have amlitelimab ...

GO TO STUDY

This is a Phase 2a PoC, treat-through, multicenter, randomized, open label, platform study in CD subjects. This platform study is designed as a series of "intervention sets" that will run in parallel but may not be initiated at the same time. Each intervention set will include 1 or more treatment arms depending on the objective of the intervention set. In addition, 1 treatment arm will be incorporated as a common comparator arm across other intervention sets. Additional "intervention sets" and/or ...

GO TO STUDY

Bowel cancer is one of the leading causes of cancer-related deaths worldwide. In the early stages of the disease, many patients can be cured with surgery. However, in the later stages, bowel cancer can return or progress even after surgery and chemotherapy. One potential way of preventing relapse is by making the patient’s immune system better at detecting and destroying any cancer cells that might remain after treatment. T cells are a type of white blood cell that play a ...

GO TO STUDY

All patients who are diagnosed with womb, bowel, or ovary cancer are recommended to have genetic-testing to see if their cancer was related to an inherited gene alteration. Identifying carriers of alterations allows novel personalised cancer treatments, prevention of second cancers, and testing of family members for cancer screening and prevention. Genetic testing requires pre-test counselling to ensure patients are informed about the impact of having a genetic test and managing the result. This ‘genetic-counselling’ has traditionally been provided by genetics ...

GO TO STUDY

The Monoclonal Antibody Medications in inflammatory Arthritis (MAMA) trial is designed to address the significant uncertainty and resulting variation in practice surrounding the effects of continuing or stopping biologics during pregnancy. There are no randomised trials which compare stopping or continuing biologics in head-to-head studies in an Autoimmune Inflammatory Arthritis (AIA) population. This study aims to fill the gap in evidence and enable evaluation of arthritis disease activity,pregnancy,and infant outcomes in women randomly allocated to continuing their biologic medication throughout ...

GO TO STUDY

This modular, multi-part, multi-arm, Phase 1/2, FIH study allows the evaluation of the safety and tolerability of CT7439, dosed as a monotherapy and in combination with anticancer treatment in participants with solid malignancies. Module 1 will initially focus on monotherapy in participants with locally advanced or metastatic solid malignancies and include dose escalation cohorts (Part A) and dose optimization cohorts (Part B) (Appendix A). In Parts A and B of Module 1, a SRC, consisting of study investigators and sponsor medical ...

GO TO STUDY